Literature DB >> 31132472

Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: A pilot study.

Muhammad Osman1, Alex Welte2, Rory Dunbar3, Rosemary Brown3, Graeme Hoddinott3, Anneke C Hesseling3, Florian M Marx4.   

Abstract

BACKGROUND: A high risk of tuberculosis (TB), chronic lung disease, and mortality have been reported among people with a history of previous TB treatment, but data from high-incidence settings remain limited. The aim of this study was to characterize general morbidity and mortality among adults who had successfully completed TB treatment in the past 5 years in a high-incidence setting in South Africa.
METHODS: Adults (≥18 years) who had completed treatment for pulmonary TB between 2013 and 2017 were randomly selected from TB treatment registers. Household visits were conducted to locate and interview former TB (FTB) patients, and bacteriological testing for TB was offered. Additional data sources were used to ascertain the vitality status of FTB patients who could not be located.
RESULTS: Addresses were located for 200 of the 223 FTB patients sampled and 89 FTB patients were contacted of whom 51 agreed to be interviewed. Approximately half reported persistent respiratory symptoms, such as shortness of breath and wheezing, and repeated lung infections. One (3.6%) of 28 patients who provided a sputum sample had culture-positive TB and another two were currently on re-treatment for TB. Fifteen deaths post treatment were ascertained, resulting in a standardized mortality ratio of 3.8 (95% confidence interval 2.3-6.3) after successful TB treatment relative to the general population.
CONCLUSIONS: In this high-incidence setting, locating and interviewing FTB patients was challenging. The study findings are consistent with a high rate of respiratory disease, including recurrent TB, and substantially elevated mortality among FTB patients.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Lung disease; Post-TB; Standardized mortality ratio; TB follow-up

Mesh:

Substances:

Year:  2019        PMID: 31132472     DOI: 10.1016/j.ijid.2019.05.024

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  3 in total

1.  Association of Xpert MTB/RIF Cycle Threshold Values with Tuberculosis Treatment Outcomes.

Authors:  Matheus de Matto Pires; Giovana Rodrigues Pereira; Márcia Silva Barbosa; Natan José Dutra Dias; Carina Secchi; Jociane Saldanha Hoff; Denise Rossato Silva
Journal:  Lung       Date:  2020-10-31       Impact factor: 2.584

2.  Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function.

Authors:  B W Allwood; M Stolbrink; N Baines; E Louw; D T Wademan; A Lupton-Smith; S Nel; D Maree; S Mpagama; M Osman; F M Marx; G Hoddinott; M Lesosky; J Rylance; K Mortimer
Journal:  Int J Tuberc Lung Dis       Date:  2021-04-01       Impact factor: 2.373

3.  Health system determinants of tuberculosis mortality in South Africa: a causal loop model.

Authors:  Muhammad Osman; Aaron S Karat; Munira Khan; Sue-Ann Meehan; Arne von Delft; Zameer Brey; Salome Charalambous; Anneke C Hesseling; Pren Naidoo; Marian Loveday
Journal:  BMC Health Serv Res       Date:  2021-04-26       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.